The plasma concentration of HDL-associated apoM is influenced by LDL receptor-mediated clearance of apoB-containing particles

Journal of Lipid Research

Volumn 53, Issue 10, 2012, Pages 2198-2204

  Christoffersen, Christina ^a   Benn, Marianne ^b   Christensen, Pernille M ^a   Gordts, Philip L S M ^c   Roebroek, Anton J M ^c   Frikke Schmidt, Ruth ^a   Tybjaerg Hansen, Anne ^a   Dahlbäck, Björn ^d   Nielsen, Lars B ^a,e  

^a Rigshospitalet   (Denmark)

^b GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^c UNIVERSITY OF LEUVEN   (Belgium)

^d LUND UNIVERSITY HOSPITAL   (Sweden)

^e UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Apolipoprotein; Familial hypercholesterolemia; Lipoprotein; Low density lipoprotein metabolism

Indexed keywords

APOLIPOPROTEIN B; APOLIPOPROTEIN M; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN RECEPTOR;

ADULT; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; FEMALE; GENE FUNCTION; GENE MUTATION; GENETIC ASSOCIATION; GENETIC CORRELATION; HETEROZYGOTE; HUMAN; LIPOLYSIS; LIPOPROTEIN BLOOD LEVEL; LIPOPROTEIN METABOLISM; MALE; METABOLIC CLEARANCE RATE; MOUSE; NONHUMAN; PLASMA CLEARANCE; PRIORITY JOURNAL; WILD TYPE;

ANIMALS; APOLIPOPROTEINS; APOLIPOPROTEINS B; FEMALE; HUMANS; LIPOCALINS; LIPOPROTEINS, HDL; LIPOPROTEINS, LDL; MALE; MICE; MICE, INBRED STRAINS; MUTATION; PROSPECTIVE STUDIES; RECEPTORS, LDL;

EID: 84866178749     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.P023697     Document Type: Article

References (37)

1. Christoffersen, C., H. Obinata, S. B. Kumaraswamy, S. Galvani, J. Ahnstrom, M. Sevvana, C. Egerer-Sieber, Y. A. Muller, T. Hla, L. B. Nielsen, et al. 2011. Endothelium-protective sphingosine-1-phosphate provided by HDL-associated apolipoprotein M. Proc. Natl. Acad. Sci. USA. 108: 9613-9618.
2. Christoffersen, C., M. Jauhiainen, M. Moser, B. Porse, C. Ehnholm, M. Boesl, B. Dahlback, and L. B. Nielsen. 2008. Effect of apolipoprotein M on high density lipoprotein metabolism and atherosclerosis in low density lipoprotein receptor knock-out mice. J. Biol. Chem. 283: 1839-1847.
3. Christoffersen, C., L. B. Nielsen, O. Axler, A. Andersson, A. H. Johnsen, and B. Dahlback. 2006. Isolation and characterization of human apolipoprotein M-containing lipoproteins. J. Lipid Res. 47: 1833-1843.
4. Wolfrum, C., M. N. Poy, and M. Stoffel. 2005. Apolipoprotein M is required for prebeta-HDL formation and cholesterol efflux to HDL and protects against atherosclerosis. Nat. Med. 11: 418-422.
5. Christoffersen, C., J. Ahnstrom, O. Axler, E. I. Christensen, B. Dahlback, and L. B. Nielsen. 2008. The signal peptide anchors apolipoprotein M in plasma lipoproteins and prevents rapid clearance of apolipoprotein M from plasma. J. Biol. Chem. 283: 18765-18772.
6. Ahnstrom, J., O. Axler, M. Jauhiainen, V. Salomaa, A. S. Havulinna, C. Ehnholm, R. Frikke-Schmidt, A. Tybjaerg-Hansen, and B. Dahlback. 2008. Levels of apolipoprotein M are not associated with the risk of coronary heart disease in two independent case-control studies. J. Lipid Res. 49: 1912-1917.
7. Axler, O., J. Ahnstrom, and B. Dahlback. 2007. An ELISA for apolipoprotein M reveals a strong correlation to total cholesterol in human plasma. J. Lipid Res. 48: 1772-1780.
8. Plomgaard, P., R. P. Dullaart, R. de Vries, A. K. Groen, B. Dahlbäck, and L. B. Nielsen. 2009. Apolipoprotein M predicts pre-beta-HDL formation: studies in type 2 diabetic and nondiabetic subjects. J. Intern. Med. 266: 258-267.
9. Christoffersen, C., T. X. Pedersen, P. L. Gordts, A. J. Roebroek, B. Dahlbäck, and L. B. Nielsen. 2010. Opposing effects of apolipoprotein m on catabolism of apolipoprotein B-containing lipoproteins and atherosclerosis. Circ. Res. 106: 1624-1634.
10. Goldstein, J. L., and M. S. Brown. 2009. The LDL receptor. Arterioscler. Thromb. Vasc. Biol. 29: 431-438.
11. Grundy, S. M., G. L. Vega, and D. W. Bilheimer. 1985. Kinetic mechanisms determining variability in low density lipoprotein levels and rise with age. Arteriosclerosis. 5: 623-630.
12. Brown, M. S., and J. L. Goldstein. 1986. A receptor-mediated pathway for cholesterol homeostasis. Science. 232: 34-47.
13. Yang, C. Y., S. H. Chen, S. H. Gianturco, W. A. Bradley, J. T. Sparrow, M. Tanimura, W. H. Li, D. A. Sparrow, H. DeLoof, and M. Rosseneu. 1986. Sequence, structure, receptor-binding domains and internal repeats of human apolipoprotein B-100. Nature. 323: 738-742.
14. Goldstein, J. L., H. Hobbs, and M. S. Brown. 2001. Familial hypercholesterolemia. In The Metabolic and Molecular Bases of Inherited Disease. 8 th edition. C. R. Scriver, A. L. Beaudet, W. S. Sly, and P. Valle, editors. McGraw-Hill, New York. 2863-2913.
15. Soria, L. F., E. H. Ludwig, H. R. Clarke, G. L. Vega, S. M. Grundy, and B. J. McCarthy. 1989. Association between a specific apolipoprotein B mutation and familial defective apolipoprotein B-100. Proc. Natl. Acad. Sci. USA. 86: 587-591.
16. Tybjaerg-Hansen, A., R. Steffensen, H. Meinertz, P. Schnohr, and B. G. Nordestgaard. 1998. Association of mutations in the apolipoprotein B gene with hypercholesterolemia and the risk of ischemic heart disease. N. Engl. J. Med. 338: 1577-1584.
17. Tybjaerg-Hansen, A., and S. E. Humphries. 1992. Familial defective apolipoprotein B-100: a single mutation that causes hypercholesterolemia and premature coronary artery disease. Atherosclerosis. 96: 91-107.
18. Jensen, H. K., L. G. Jensen, H. Meinertz, P. S. Hansen, N. Gregersen, and O. Faergeman. 1999. Spectrum of LDL receptor gene mutations in Denmark: implications for molecular diagnostic strategy in het er ozygous familial hypercholesterolemia. Atherosclerosis. 146: 337-344.
19. Tybjaerg-Hansen, A., H. K. Jensen, M. Benn, R. Steffensen, G. Jensen, and B. G. Nordestgaard. 2005. Phenotype of heterozygotes for low-density lipoprotein receptor mutations identified in different background populations. Arterioscler. Thromb. Vasc. Biol. 25: 211-215.
20. Appleyard, M., A. Tybjaerg-Hansen, G. Jensen, P. Schnohr, and J. Nyboe. The Copenhagen City Heart study. Østerbroundersøgelsen. A book of tables with data from the first examination (1976-1978) and a five-year follow-up (1981-1983) 1989. Scand. J. Soc. Med. 170 (Suppl 41): 1-160.
21. Frikke-Schmidt, R., B. G. Nordestgaard, M. C. Stene, A. A. Sethi, A. T. Remaley, P. Schnohr, P. Grande, and A. Tybjaerg-Hansen. 2008. Association of loss-of-function mutations in the ABCA1 gene with high-density lipoprotein cholesterol levels and risk of ischemic heart disease. J. Am. Med. Assoc. 299: 2524-2532.
22. Schnohr, P., G. Jensen, H. Scharling, and M. Appleyard. 2001 Eur Heart J. 3: H1-H83.
23. Benn, M., B. G. Nordestgaard, J. S. Jensen, and A. Tybjaerg-Hansen. 2007. Polymorphisms in apolipoprotein B and risk of ischemic stroke. J. Clin. Endocrinol. Metab. 92: 3611-3617.
24. Benn, M., B. G. Nordestgaard, J. S. Jensen, K. Nilausen, H. Meinertz, and A. Tybjaerg-Hansen. 2005. Mutation in apolipoprotein B associated with hypobetalipoproteinemia despite decreased binding to the low density lipoprotein receptor. J. Biol. Chem. 280: 21052-21060.
25. Benn, M. 2009. Apolipoprotein B levels, APOB alleles, and risk of ischemic cardiovascular disease in the general population, a review. Atherosclerosis. 206: 17-30.
26. Kornerup, K., B. G. Nordestgaard, B. Feldt-Rasmussen, K. Borch-Johnsen, K. S. Jensen, and J. S. Jensen. 2002. Transvascular low-density lipoprotein transport in patients with diabetes mellitus (type 2): a noninvasive in vivo isotope technique. Arterioscler. Thromb. Vasc. Biol. 22: 1168-1174.
27. Benn, M., B. G. Nordestgaard, J. S. Jensen, P. Grande, H. Sillesen, and A. Tybjaerg-Hansen. 2005. Polymorphism in APOB associated with increased low-density lipoprotein levels in both genders in the general population. J. Clin. Endocrinol. Metab. 90: 5797-5803.
28. Gordts, P. L., S. Reekmans, A. Lauwers, A. Van Dongen, L. Verbeek, and A. J. Roebroek. 2009. Inactivation of the LRP1 intracellular NPxYxxL motif in LDLR-deficient mice enhances postprandial dyslipidemia and atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 29: 1258-1264.
29. Kappelle, P. J., J. Ahnström, B. D. Dikkeschei, R. de Vries, W. J. Sluiter, B. H. Wolffenbuttel, A. van Tol, L. B. Nielsen, B. Dahlbäck, and R. P. Dullaart. 2010. Plasma apolipoprotein M responses to statin and fibrate administration in type 2 diabetes mellitus. Atherosclerosis. 213: 247-250.
30. Kappelle, P. J., G. Lambert, B. Dahlback, L. B. Nielsen, and R. P. Dullaart. 2011. Relationship of plasma apolipoprotein M with proprotein convertase subtilisin-kexin type 9 levels in non-diabetic subjects. Atherosclerosis. 214: 492-494.
31. Duan, J., B. Dahlback, and B. O. Villoutreix. 2001. Proposed lipocalin fold for apolipoprotein M based on bioinformatics and sitedirected mutagenesis. FEBS Lett. 499: 127-132.
32. Faber, K., V. Hvidberg, S. K. Moestrup, B. Dahlback, and L. B. Nielsen. 2006. Megalin is a receptor for apolipoprotein M, and kidney-specific megalin-deficiency confers urinary excretion of apolipoprotein M. Mol. Endocrinol. 20: 212-218.
33. Karuna, R., R. Park, A. Othman, A. G. Holleboom, M. M. Motazacker, I. Sutter, J. A. Kuivenhoven, L. Rohrer, H. Matile, T. Hornemann, et al. 2011. Plasma levels of sphingosine-1-phosphate and apolipoprotein M in patients with monogenic disorders of HDL metabolism. Atherosclerosis. 219: 855-863.
34. Xu, N., and B. Dahlback. 1999. A novel human apolipoprotein (apoM). J. Biol. Chem. 274: 31286-31290.
35. Ishibashi, S., M. S. Brown, J. L. Goldstein, R. D. Gerard, R. E. Hammer, and J. Herz. 1993. Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery. J. Clin. Invest. 92: 883-893.
36. Dullaart, R. P., P. Plomgaard, R. de Vries, B. Dahlbäck, and L. B. Nielsen. 2009. Plasma apolipoprotein M is reduced in metabolic syndrome but does not predict intima media thickness. Clin. Chim. Acta. 406: 129-133.
37. Kronenberg, F., K. Ikewaki, J. R. Schaefer, P. Konig, and H. Dieplinger. 2007. Kinetic studies of atherogenic lipoproteins in hemodialysis patients: do they tell us more about their pathology? Semin. Dial. 20: 554-560.